The guidance revisions consist of the approximated effect of existing tariffs on U.S. products shipped to China, but not Trump's prepared pharmaceutical tariffs.
Source
Related Articles
Bristol Myers Squibb tops quarterly price quotes, walkings outlook as drugmaker braces for tariffs